Medicine composition for treating disease caused by immunity imbalance and poria cocos extract

A technology for immune disorders and medicines is applied in the field of pharmaceutical compositions and Poria cocos extracts for the treatment of diseases caused by immune disorders, and can solve the problems of undiscovered lanostane and the like

Inactive Publication Date: 2015-10-07
SINPHAR TIAN LI PHARMA
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Lanostanes have so far not been found to be effective in treating allergies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating disease caused by immunity imbalance and poria cocos extract
  • Medicine composition for treating disease caused by immunity imbalance and poria cocos extract
  • Medicine composition for treating disease caused by immunity imbalance and poria cocos extract

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Take 30 kg of Poria cocos produced in Yunnan, grind it into powder, extract with 120 L of alcohol (concentration 95%) for 24 hours, and separate by filtration. The aforementioned extraction and solid-liquid separation were repeated three times. The filtrates were combined and concentrated to obtain 265.2 g of dry extract. The dry extract was then extracted with a two-phase extractant (hexane: 95% methanol = 1:1). The methanol layer was taken out and pre-concentrated to obtain 246.9 g of dry solid. The dry solid is separated by silica gel column chromatography, and the silica gel column is filled with silica gel 10-40 times the weight of the dry solid, purchased from Merck Company, Silica gel 60, 70-230 mesh. Using dichloromethane / methanol mixture as eluent, elution was carried out at the ratio of 96:4, 90:10, and 0:100 in sequence, and the eluate was subjected to silica gel thin-layer chromatography Method (Thin Layer Chromatography) (ultraviolet light and iodine for...

Embodiment 2

[0052] After boiling 100 kg of Poria cocos with 800 kg of water for 3 hours, let it stand and cool to 50°C, adjust the solution to pH 11 with 5N NaOH, and then stir the solution for 3 hours. Then use a centrifuge to separate the liquid and solid, then add the solid with 800 kg of water, adjust the pH to 11 with NaOH, stir and separate with a centrifuge, and remove the solid. The two liquids were combined, and the liquid was concentrated in vacuo at 50°C to 100 kg of solution, and then 3N HCl was added to pH 6.5, resulting in a precipitate. Separate the precipitate, and then with 40L H 2 O was washed, and then the precipitate was separated with a centrifuge, and 8 L of water was added to spray dry (spray dry) to obtain about 380 g of powder. Then extract the powder three times with 4L of alcohol, combine the extracts and concentrate to obtain 238.9 grams of alcohol extract (PCE), and then separate the extract by HPLC. The main components of each gram of the extract are K2185.9...

Embodiment 3

[0054] Experiment of Treating Asthmatic Mice with Poria Cocos Extract and Its Purified Lanostane Compounds

[0055] In this example, after the mice were sensitized with ovalbumin (OVA) as an allergen, the presence of OVA-specific IgE antibodies in the mice confirmed that the animals had been induced with symptoms of asthma. During the experiment, each group was fed with Poria cocos extract and its purified lanostane compounds, and one month later, the airway hyperresponsiveness of the lungs was tested on the asthmatic mice as an important indicator for determining the degree of asthma in the mice . This embodiment also detects various immune cells in the bronchoalveolar lavage fluid of mice to observe whether various immune cells are affected, especially whether neutrophils and eosinophils are affected. In this embodiment, chemokine (Eotaxin) is also used as an important observation factor to observe whether there is a major change in the secretion of cytokines.

[0056] exp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application to preparing a medicine for treating a disease caused by immunity imbalance of a mammal with a tumulosic acid compound K2-1 or other pharmaceutically acceptable salt thereof as an active ingredient, wherein the disease caused by immunity imbalance is allergy, and the allergy is allergic asthma; and the tumulosic acid compound K2-1 is of a structure represented by a chemical formula shown in the specification, wherein R2=OH.

Description

[0001] This application is a divisional application of an invention patent application with an application date of June 24, 2008, an application number of 200880129698.X, and a title of "Pharmaceutical Composition and Poria Cocos Extract for Treating Diseases Caused by Immune Disorders". technical field [0002] The present invention relates to a new application of using lanostane compounds to treat diseases caused by immune disorders such as allergies. Background technique [0003] Immunoglobulin E (IgE) is a type of immunoglobulin (or "antibody") molecule. The concentration of IgE in the human body is lower than that of other types of immunoglobulins such as IgG, IgM, IgA, IgD, etc. IgE has long been considered to play an important role in the body's defense against parasites, but this role has not been clearly established as necessary and beneficial, especially in developed countries where parasite infection is not a serious problem. However, its role as a mediator of im...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/575A61P37/08A61P17/06
Inventor 林汉钦吴文勉
Owner SINPHAR TIAN LI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap